tipifarnib has been researched along with tretinoin in 2 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (tretinoin) | Trials (tretinoin) | Recent Studies (post-2010) (tretinoin) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 23,654 | 1,083 | 6,085 |
| Protein | Taxonomy | tipifarnib (IC50) | tretinoin (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Amyloid-beta precursor protein | Homo sapiens (human) | 0.18 | |
| Adenosine receptor A3 | Homo sapiens (human) | 5.275 | |
| Retinoic acid receptor alpha | Homo sapiens (human) | 2.2542 | |
| 60 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 5.3 | |
| Retinoic acid receptor beta | Homo sapiens (human) | 0.7537 | |
| Retinoic acid receptor alpha | Mus musculus (house mouse) | 0.0057 | |
| Retinoic acid receptor gamma | Homo sapiens (human) | 0.0064 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 5.275 | |
| Retinoic acid receptor gamma | Mus musculus (house mouse) | 0.004 | |
| Retinoic acid receptor beta | Mus musculus (house mouse) | 0.005 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 0.576 | |
| Nuclear receptor ROR-alpha | Homo sapiens (human) | 0.1995 | |
| Alpha-synuclein | Homo sapiens (human) | 3 | |
| Cellular retinoic acid-binding protein 1 | Gallus gallus (chicken) | 0.5233 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.358 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 5.275 | |
| Retinoic acid receptor RXR-gamma | Homo sapiens (human) | 0.35 | |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | 0.1995 | |
| 10 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 5.3 | |
| Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | 0.82 | |
| 60 kDa chaperonin | Escherichia coli | 6.7 | |
| 10 kDa chaperonin | Escherichia coli | 6.7 | |
| Nuclear receptor ROR-beta | Homo sapiens (human) | 0.1259 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, Y | 1 |
| Karp, J | 1 |
2 other study(ies) available for tipifarnib and tretinoin
| Article | Year |
|---|---|
[Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biomarkers, Tumor; Child; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Loss of Heterozygosity; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Rituximab; Tretinoin | 2007 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |